Latest & greatest articles for colon cancer screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colon cancer screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colon cancer screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colon cancer screening

101. Population Screening Act: bowel cancer screening by pill camera

Population Screening Act: bowel cancer screening by pill camera Population Screening Act: bowel cancer screening by pill camera Population Screening Act: bowel cancer screening by pill camera Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. Population Screening Act: bowel cancer screening (...) by pill camera. The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2013/31. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Capsule Endoscopys; Diagnostic Techniques, Digestive System; Gamma Cameras; Intestinal Neoplasms; Netherlands Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax

2013 Health Technology Assessment (HTA) Database.

102. Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer

Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer Executive Summary 1 Translation of the executive summary of the final report “Bewertung des Nutzens einer Früherkennungs- untersuchung für Personen unter 55 Jahren mit familiärem Darmkrebsrisiko” (Version 1.0; Status: 29 May 2013). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely (...) authoritative and legally binding. IQWiG Reports – Commission No. S11-01 Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer 1 Executive summary of final report S11-01 Version 1.0 Screening for colorectal cancer in persons with a family history 29 May 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Assessment of the benefit

2013 Institute for Quality and Efficiency in Healthcare (IQWiG)

103. Screening based on risk for colorectal cancer is the most cost-effective approach

Screening based on risk for colorectal cancer is the most cost-effective approach Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 NHS Economic Evaluation Database.

104. Systematic review: One-on-one education and client reminders increase uptake of colorectal, breast and cervical cancer screening

Systematic review: One-on-one education and client reminders increase uptake of colorectal, breast and cervical cancer screening One-on-one education and client reminders increase uptake of colorectal, breast and cervical cancer screening | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here One-on-one education and client reminders increase uptake of colorectal, breast and cervical cancer screening Article Text Nursing issues Systematic

2013 Evidence-Based Nursing

105. [Efficacy and safety of genetic tests for screening of colorectal cancer]

of colorectal cancer (positive likelihood ratios of between 5.8 and 18.75), although with values to rule out the disease that were only acceptable (negative likelihood ratios between 0.26 and 0.63). CONCLUSION: Nevertheless, before genetic blood tests can be incorporated into the health system as part of a screening program, it is essential to resolve outstanding problems such as the appropriate selection of the target population, the test obtaining a correct classification of the patients to study by means (...) of an appropriate configuration of the final gene or panel of genes, the planning of a working protocol in which the correct multidisciplinary coordination is achieved; and finally the benefit that would be obtained with regards to the changes in the prognosis and its repercussion on the disease and/or death rate. Final publication URL Additional data URL Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms; Genetic Testings; Mass Screening Language Published Spanish Country

2012 Health Technology Assessment (HTA) Database.

106. [Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program]

[Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program] Test immunochimique de recherche de sang occulte dans les selles. Détermination d'un seuil de positivité pour démarrer les projets de démonstration du PQDCCR [Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program] Test (...) immunochimique de recherche de sang occulte dans les selles. Détermination d'un seuil de positivité pour démarrer les projets de démonstration du PQDCCR [Immunochemical fecal occult blood. Determination of a positivity threshold for the upcoming demonstration projects under Québec's colorectal cancer screening program] L'Institut national d'excellence en sante et en services sociaux (INESSS) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2012 Health Technology Assessment (HTA) Database.

107. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services (Abstract)

Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services Screening reduces mortality from breast, cervical, and colorectal cancers. The Guide to Community Preventive Services previously conducted systematic reviews on the effectiveness of 11 interventions to increase screening for these cancers. This article presents results of updated systematic reviews for nine (...) and cervical cancer screening); and reducing structural barriers (breast cancer and FOBT screening) were reaffirmed or unchanged. Evidence remains insufficient to determine effectiveness for the remaining screening tests and intervention categories.Findings indicate new and reaffirmed interventions effective in promoting recommended cancer screening, including colorectal cancer screening. Findings can be used in community and healthcare settings to promote recommended care. Important research gaps also

2012 EvidenceUpdates

108. A single FIT (≥ 50 ng Hb/mL) detected 38% of screen-detected advanced colorectal neoplasia. (Abstract)

A single FIT (≥ 50 ng Hb/mL) detected 38% of screen-detected advanced colorectal neoplasia. 23165686 2013 01 28 2012 11 20 1539-3704 157 10 2012 Nov 20 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. A single FIT (≥ 50 ng Hb/mL) detected 38% of screen-detected advanced colorectal neoplasia. JC5-10 10.7326/0003-4819-157-10-201211200-02010 Logan Richard F RF Eastern Bowel Cancer Screening Hub for England Nottingham University Hospitals Nottingham, England, UK. eng Comment Journal

2012 Annals of Internal Medicine

109. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy Full Text available with Trip Pro

of complications (bowel perforation and bleeding) and management of adenoma and various stages of colorectal cancer. These costs were taken from various sources that included expert opinion (based on discussion with the National Cancer Screening Service, test suppliers and laboratory staff), Department of Health and Children salary scales, UK sources, Irish private health insurer fee schedules, diagnostic-related group costs and a published study. Costs were in Euros (€). The price year was 2008. A 4% annual (...) of Cancer 2012; 106(5): 805-816 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Colorectal Neoplasms /diagnosis /economics /mortality; Cost-Benefit Analysis; Early Detection of Cancer /economics /methods; Feces; Female; Guaiac; Humans; Ireland; Male; Mass Screening /economics /methods; Middle Aged; Occult Blood; Sigmoidoscopy /economics AccessionNumber 22012011444 Date bibliographic record published 09/06/2012 Date abstract record published 25/10/2012 NHS

2012 NHS Economic Evaluation Database.

110. Flexible sigmoidoscopy screening reduced colorectal cancer incidence and mortality in older adults. (Abstract)

Flexible sigmoidoscopy screening reduced colorectal cancer incidence and mortality in older adults. 22986395 2012 12 03 2012 09 18 1539-3704 157 6 2012 Sep 18 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Flexible sigmoidoscopy screening reduced colorectal cancer incidence and mortality in older adults. JC3-3 10.7326/0003-4819-157-6-201209180-02003 Kahi Charles J CJ Imperiale Thomas F TF eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 N Engl J Med

2012 Annals of Internal Medicine

111. Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening Full Text available with Trip Pro

; 141(5): 1648-1655.e1 PubMedID DOI Original Paper URL Other publications of related interest Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Computers and Biomedical Research 1999; 32: 13-33. Indexing Status Subject indexing assigned by NLM MeSH Adenoma /diagnosis /epidemiology; Adult; Age Factors; Aged; Colonoscopy; Colorectal Neoplasms /diagnosis /epidemiology; Cost-Benefit Analysis; Early Detection of Cancer (...) of the screening strategies and FIT cut-off levels. The time horizon was the lifetime of the patient (maximum 30 years). The authors did not explicitly state the perspective. Effectiveness data: Many parameters, such as the natural history of colorectal cancer, treatment effectiveness, and mortality, were those used in the MISCAN-COLON model. The specificity and sensitivity of the FITs with different cut-off levels were from two published randomised controlled trials, conducted in the Netherlands

2012 NHS Economic Evaluation Database.

112. Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Full Text available with Trip Pro

-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy. Diseases of the Colon and Rectum 2011; 54(7): 876-886 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Aged; Colonoscopy /economics; Colorectal Neoplasms /diagnosis /economics /epidemiology; Cost-Benefit Analysis; Female; France /epidemiology; Guaiac /economics; Guidelines as Topic; Humans; Immunologic Tests /economics /methods; Incidence; Indicators (...) Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I Record Status This is a critical abstract of an economic evaluation that meets

2012 NHS Economic Evaluation Database.

113. Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians. (Abstract)

Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians. Colorectal cancer is the second leading cause of cancer-related deaths for men and women in the United States. The American College of Physicians (ACP) developed this guidance statement for clinicians by assessing the current guidelines developed by other organizations on screening for colorectal cancer. When multiple guidelines are available on a topic or when existing guidelines conflict, ACP (...) by the Institute for Clinical Systems Improvement, the U.S. Preventive Services Task Force, and the American College of Radiology. GUIDANCE STATEMENT 1: ACP recommends that clinicians perform individualized assessment of risk for colorectal cancer in all adults. GUIDANCE STATEMENT 2: ACP recommends that clinicians screen for colorectal cancer in average-risk adults starting at the age of 50 years and in high-risk adults starting at the age of 40 years or 10 years younger than the age at which the youngest

2012 Annals of Internal Medicine

114. Bowel Cancer Screening

Bowel Cancer Screening POSITION PAPER ROYAL AUSTRALASIAN COLLEGE OF SURGEONS Subject: Bowel Cancer Screening Ref. No. REL_MPR_001 Document Owner: Division: Authorised By: Page 1 of 3 Director Relationships & Advocacy Council Original Issue: Version: Approval Date: Review Date: May 2012 1 May 2012 May 2015 BOWEL CANCER SCREENING Background Cancer Council Australia reports that bowel cancer, also known as colorectal or large bowel cancer, is the second most common cause of death from cancer (...) and all monitoring and evaluation data has been analysed. This will determine the level of participation, the number of cancers that were detected, the stage of the disease at diagnosis, the impact on health services and the costs involved.” POSITION PAPER ROYAL AUSTRALASIAN COLLEGE OF SURGEONS Subject: Bowel Cancer Screening Ref. No. REL_MPR_001 Document Owner: Division: Authorised By: Page 3 of 3 Director Relationships & Advocacy Council Original Issue: Version: Approval Date: Review Date: May 2012

2012 Publication 80

115. Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer 2

. Alberts DS, Maratinez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846–853. 14. Lieberman DA, Weiss DG, Harford WV, et al. Five year colon surveillanceafterscreeningcolonoscopy.Gastroenterology2007; 133:1077–1085. 15. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352:2061–2068. 16. Baxter NN, Sutradhar R, Forbes SS, et al. Analysis (...) - ferences in proximal polyp/cancer morphology, the skill of the endoscopist, and variable quality of colonoscopy. Serrated polyps and some classic adenomatous polyps in the proximal colon may be challenging to detect if they are ?at, covered with mucus, or behind folds. Most prior studies of colonoscopy have failed to report on the quality of the colonoscopy examinations. A second hypothesis is that neoplastic lesions of the proximal colon may biolog- ically differ from distal lesions and progress

2012 American College of Gastroenterology

116. Guidelines for colonoscopy surveillance after screening and polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

. Alberts DS, Maratinez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97:846–853. 14. Lieberman DA, Weiss DG, Harford WV, et al. Five year colon surveillanceafterscreeningcolonoscopy.Gastroenterology2007; 133:1077–1085. 15. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. N Engl J Med 2005; 352:2061–2068. 16. Baxter NN, Sutradhar R, Forbes SS, et al. Analysis (...) - ferences in proximal polyp/cancer morphology, the skill of the endoscopist, and variable quality of colonoscopy. Serrated polyps and some classic adenomatous polyps in the proximal colon may be challenging to detect if they are ?at, covered with mucus, or behind folds. Most prior studies of colonoscopy have failed to report on the quality of the colonoscopy examinations. A second hypothesis is that neoplastic lesions of the proximal colon may biolog- ically differ from distal lesions and progress

2012 American Society for Gastrointestinal Endoscopy

117. Preliminary analysis of the cost-effectiveness of the National Bowel Cancer Screening Program: demonstrating the potential value of comprehensive real world data

and monitoring adenomas with a high-risk of developing colorectal cancer or identifying and treating cancer at an earlier stage. The distribution of disease stage at detection was from the NBCSP for both screened and unscreened groups. Data on five-year survival from time of diagnosis of colorectal cancer were from BioGrid Australia (a large database). After five years, survival was assumed to revert to the normal age-specific life expectancy from Australian government statistics. Other key parameters (...) of using real-world data from a case study of Australia's National Bowel Cancer Screening Program (NBCSP) to inform cost-effectiveness. Interventions Australia's NBCSP was compared with no screening. The screening programme consisted of an invitation to be screened, a faecal occult blood test (FOBT) for those who participated, colonoscopy for those with a positive result, resection or surveillance of any adenomas found, and treatment for any colorectal cancer. Without screening, detection of adenomas

2012 NHS Economic Evaluation Database.

118. Population Screening Act: accelerated repeat screening for bowel cancer

: accelerated repeat screening for bowel cancer. The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2012/01. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Colorectal Neoplasms; Mass Screenings Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523 Email: info@gr.nl (...) Population Screening Act: accelerated repeat screening for bowel cancer Population Screening Act: accelerated repeat screening for bowel cancer Population Screening Act: accelerated repeat screening for bowel cancer Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. Population Screening Act

2012 Health Technology Assessment (HTA) Database.

119. Interventions to promote colorectal cancer screening: an integrative review Full Text available with Trip Pro

A, Breslau ES. Interventions to promote colorectal cancer screening: an integrative review. Nursing Outlook 2012; 60(4): 172-181.e13 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /prevention & Early Detection of Cancer /statistics & Health Promotion /methods; Humans; Randomized Controlled Trials as Topic; control; numerical data AccessionNumber 12012041142 Date bibliographic record published 18/12/2012 Date abstract record published 07/10/2013 (...) Interventions to promote colorectal cancer screening: an integrative review Interventions to promote colorectal cancer screening: an integrative review Interventions to promote colorectal cancer screening: an integrative review Rawl SM, Menon U, Burness A, Breslau ES CRD summary This review concluded that several effective interventions to promote colorectal cancer screening were identified, but trial limitations made it difficult to draw definitive conclusions. The review had numerous

2012 DARE.

120. Fecal DNA testing in screening for colorectal cancer in average-risk adults

in asymptomatic, average-risk patients. There is also insufficient evidence for the harms, analytic validity, and acceptability of testing in comparison to other screening modalities. Existing evidence has little or no applicability to currently available fecal DNA testing. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Biomarkers, Tumor; Colorectal Neoplasms; DNA, Neoplasm; Fecess Language Published English Country of organisation United States English summary An English language (...) Fecal DNA testing in screening for colorectal cancer in average-risk adults Fecal DNA testing in screening for colorectal cancer in average-risk adults Fecal DNA testing in screening for colorectal cancer in average-risk adults Lin JS, Webber EM, Beil TL, Goddard KA, Whitlock EP Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lin JS

2012 Health Technology Assessment (HTA) Database.